The global lyophilized drugs market has witnessed significant growth in recent years owing to the advantages of lyophilized drugs such as ease in transportation and longer shelf-life. Lyophilized drugs are freeze-dried medicines that can be stored easily at room temperature without refrigeration and are more stable compared to conventional liquid medicines. They do not require sterile facilities for compounding and have minimal risk of contamination. As lyophilized medicines retain their potency much longer than liquid medications, they offer greater convenience and accessibility to patients, especially in remote areas with unreliable refrigeration.
The global lyophilized drugs market is estimated to be valued at US$ 366.11 Mn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the lyophilized drugs market is the growing focus on developing new lyophilized biologics. Biologics such as monoclonal antibodies and vaccines are increasingly being produced and marketed in lyophilized forms owing to their thermal and chemical instability in liquid state. Lyophilization helps improve their stability and ease of administration while maintaining clinical efficacy. Many pharmaceutical companies are engaging in R&D activities to expand their portfolios of lyophilized biological products for various indications such as cancer, diabetes, cardiovascular diseases etc. This is expected to drive significant growth of the lyophilized drugs market.
Threat of new entrants: The lyophilized drugs market requires substantial investments in R&D, manufacturing facilities and marketing. This poses high entry barriers and limits threat of new entrants.
Bargaining power of buyers: Buyers have moderate bargaining power as there are numerous established players in the market providing competitive pricing and product offerings.
Bargaining power of suppliers: Suppliers have moderate bargaining power owing to availability of substitute raw materials and services.
Threat of new substitutes: Threat of substitutes is low as lyophilized drugs offer unique stability and dosing advantages over alternative formulations.
Competitive rivalry: The market is highly competitive with focus on new product launches, partnerships and expansions.
The Global Lyophilized Drugs Market Size is expected to witness high growth over the forecast period of 2024 to 2031. The global lyophilized drugs market is estimated to be valued at US$ 366.11 Mn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2024 to 2031.
Regional analysis: North America region currently dominates the market and is expected to continue its dominance over the forecast period owing to presence of major players and rising research activities. The Asia Pacific region is expected to grow at the fastest pace during the forecast period with increasing healthcare investments and expansion of key players in emerging markets.
Key players: Key players operating in the lyophilized drugs market are BASF SE, Evonik Industries AG, Clariant AG, DuPont de Nemours, Inc., Albemarle Corporation, Arkema SA, Johnson Matthey PLC, Mitsubishi Chemical Corporation, Honeywell International Inc., Shell Catalysts & Technologies, W. R. Grace & Co., Haldor Topsoe A/S, Dow Chemical Company, CRI Catalyst Company, and Sud-Chemie India Pvt. Ltd. (Clariant India Ltd.). The players are focused on new product launches and partnerships to strengthen their market position.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it